2-Bromo-LSD D-Tartrate

Synonyms: BOL-148 D-Tartrate; Bromolysergide D-Tartrate
2-Bromo-LSD D-Tartrate (BOL-148 D-Tartrate) 是一种能透过血脑屏障的 5-HT2A 部分激动剂和竞争性部分拮抗剂,在 5-HT2A 受体上同时发挥强效部分激动剂(针对 Gq 解离的 EC50 = 0.81 nM)和强效部分拮抗剂(针对 Gq 解离的 KB = 0.18 nM)的作用,对包括 5-HT2A 在内的多种胺能 GPCR 表现出部分激动作用,缺乏 5-HT2B 激动作用,可诱导树突生成和棘突生成,并逆转慢性应激的行为影响、增加小鼠的主动应对行为。
产品编号: MS-J18573 纯度: 99.91% CAS No.: 2855123-30-5 分子式: C20H24BrN3O.1/2C4H6O6 分子量: 477.39
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

2-Bromo-LSD D-Tartrate (BOL-148 D-Tartrate) 是一种能透过血脑屏障的 5-HT2A 部分激动剂和竞争性部分拮抗剂,在 5-HT2A 受体上同时发挥强效部分激动剂(针对 Gq 解离的 EC50 = 0.81 nM)和强效部分拮抗剂(针对 Gq 解离的 KB = 0.18 nM)的作用,对包括 5-HT2A 在内的多种胺能 GPCR 表现出部分激动作用,缺乏 5-HT2B 激动作用,可诱导树突生成和棘突生成,并逆转慢性应激的行为影响、增加小鼠的主动应对行为。

生物实验数据

生物活性 2-Bromo-LSD D-Tartrate (BOL-148 D-Tartrate) is a blood-brain barrier-permeable 5-HT2A partial agonist and competitive partial antagonist that acts at the 5-HT2A receptor as both a potent partial agonist (EC50 = 0.81 nM for Gq dissociation) and a potent partial antagonist (KB = 0.18 nM for Gq dissociation), exhibits partial agonism at multiple aminergic GPCRs including 5-HT2A, lacks 5-HT2B agonist activity, induces dendritogenesis and spinogenesis, and reverses the behavioral effects of chronic stress and increases active coping behavior in mice.
IC50 & Target 5-HT2A Receptor:0.81 nM (EC50)
体外研究
(In Vitro)

2-Bromo-LSD D-Tartrate 在 5-HT2A 受体上同时发挥强效部分激动剂 (针对 Gq 解离的 EC50 = 0.81 nM,Eₘₐₓ = 59.8%) 和强效部分拮抗剂 (针对 Gq 解离的 KB = 0.18 nM) 的作用。
2-Bromo-LSD D-Tartrate 对 hERG 通道产生微弱的阻断作用 (IC50 = 31.6 μM)。
2-Bromo-LSD D-Tartrate (1-10 μM; 3 h) 可促进原代大鼠皮质神经元的树突发生、树突棘密度。

体内研究
(In Vivo)

2-Bromo-LSD D-Tartrate (0.125-4 mg/kg;腹腔注射) 可剂量依赖性地增加大鼠纹状体中 DOPA 的蓄积,在 2-4 mg/kg 剂量下达到最大效应,且该效应强于等摩尔浓度的 LSD;同时它可作为拮抗剂逆转 Apomorphine (MS-M00438) 诱导的 DOPA 蓄积减少,并阻断 LSD 对 GBL 刺激的 DOPA 蓄积的抑制作用。
2-Bromo-LSD D-Tartrate (0.125-2.0 mg/kg;腹腔注射) 与 LSD 联合时,相较于相同剂量的单独使用 2-Bromo-LSD D-Tartrate,并未引起纹状体 DOPA 累积量的统计学显著变化。
2-Bromo-LSD D-Tartrate (0.1-10 mg/kg;腹腔注射) 不会在雄性 C57BL/6J 小鼠中诱导致幻剂相关的甩头反应,但会呈剂量依赖性地阻断 DOI 诱导的甩头反应,在 3 mg/kg 剂量下抑制率达 76%。

Animal Model: Sprague-Dawley (male, 188-298 g)
Dosage: 0.125 mg/kg; 0.250 mg/kg; 0.5 mg/kg; 2 mg/kg; 4 mg/kg
Administration: i.p.; single dose; 30 minutes before sacrifice
Result: Increased striatal DOPA accumulation to 1386 ± 106 ng/g (n=6), significantly higher than saline control (1042 ± 77 ng/g, p<0.001) at 0.125 mg/kg.
Increased striatal DOPA accumulation to 1951 ± 380 ng/g (n=6), significantly higher than saline control (p<0.001) at 0.250 mg/kg.
Increased striatal DOPA accumulation to 1924 ± 131 ng/g (n=9), significantly higher than saline control (p<0.001) at 0.5 mg/kg; restored apomorphine (0.5 mg/kg)-reduced DOPA accumulation to 781 ± 28 ng/g from 472 ± 51 ng/g, and apomorphine (5 mg/kg)-reduced levels to 594 ± 42 ng/g from 249 ± 31 ng/g; showed no effect on reserpine-induced increased DOPA accumulation (2465 ± 243 ng/g vs.
2618 ± 136 ng/g, p=N.S.) and did not inhibit GBL-induced increased DOPA accumulation.
Increased striatal DOPA accumulation to 2630 ± 169 ng/g (n=6), significantly higher than saline control (p<0.001) at 2 mg/kg; produced larger maximum increase than equimolar LSD; restored apomorphine (0.5 mg/kg)-reduced DOPA accumulation to 2888 ± 111 ng/g from 472 ± 51 ng/g (levels not significantly different from BOL 2 mg/kg alone), and apomorphine (5 mg/kg)-reduced levels to 828 ± 190 ng/g from 249 ± 31 ng/g; showed no effect on haloperidol-induced or reserpine-induced increased DOPA accumulation, did not inhibit cerebral hemisection-induced increased DOPA accumulation on the sectioned side (1915 ± 215 ng/g vs.
2647 ± 400 ng/g, p=N.S.) but increased levels on the unsectioned side to 2058 ± 158 ng/g from 901 ± 232 ng/g (p<0.02); blocked LSD-induced inhibition of GBL-stimulated DOPA accumulation.
Significantly increased striatal DOPA accumulation compared to saline control and produced larger maximum increase than equimolar LSD at 4 mg/kg.
Animal Model: C57BL/6J (male and female, 7-8 weeks old)
Dosage: 0.3 mg/kg; 1.0 mg/kg; 3.0 mg/kg
Administration: three dose
Result: Increased time spent in the center of the OFT by 88.18 ± 18.89 seconds (female, 1.0 mg/kg) and showed a non-significant trend (female, 3.0 mg/kg).
Reduced FST immobility time by 35.18 ± 10.03 seconds (female, 1.0 mg/kg), 20.89 ± 8.249 seconds (male, 0.3 mg/kg), 27.27 ± 8.226 seconds (male, 1.0 mg/kg), and 31.36 ± 8.226 seconds (male, 3.0 mg/kg).
Showed a non-significant trend toward increased center time in the OFT (male, all doses).
Increased average PFC spine density compared to vehicle controls (both sexes, 1.0 mg/kg).
性状 固体
颜色 Light yellow to brown

化学信息

分子量 477.39
分子式 C20H24BrN3O.1/2C4H6O6
CAS No. 2855123-30-5
别名 BOL-148 D-Tartrate; Bromolysergide D-Tartrate

储存&溶解度

储存方式

4°C, stored under nitrogen

*In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (209.47 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.0947 mL10.4736 mL20.9472 mL52.3681 mL
5 mM0.4189 mL2.0947 mL4.1894 mL10.4736 mL
10 mM0.2095 mL1.0474 mL2.0947 mL5.2368 mL
15 mM0.1396 mL0.6982 mL1.3965 mL3.4912 mL
20 mM0.1047 mL0.5237 mL1.0474 mL2.6184 mL
25 mM0.0838 mL0.4189 mL0.8379 mL2.0947 mL
30 mM0.0698 mL0.3491 mL0.6982 mL1.7456 mL
40 mM0.0524 mL0.2618 mL0.5237 mL1.3092 mL
50 mM0.0419 mL0.2095 mL0.4189 mL1.0474 mL
60 mM0.0349 mL0.1746 mL0.3491 mL0.8728 mL
80 mM0.0262 mL0.1309 mL0.2618 mL0.6546 mL
100 mM0.0209 mL0.1047 mL0.2095 mL0.5237 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础